Weekly Cerus Corporation (NASDAQ:CERS) Ratings on Jun 29, 2018

June 29, 2018 - By Matthew Medley

During Q1 2018 the big money sentiment increased to 1.84. That’s change of 0.39, from 2017Q4’s 1.45. 5 investors sold all, 27 reduced holdings as Cerus Corporation ratio increased. 38 rose holdings while 21 funds amassed holdings. Funds hold 69.09 million shares thus 17.19% more from 2017Q4’s 58.96 million shares.
Amalgamated Retail Bank holds 17,056 shs or 0% of its capital. Citigroup reported 0% stake. Utd Services Automobile Association reported 0% stake. California State Teachers Retirement System stated it has 193,666 shs or 0% of all its holdings. Jump Trading Lc invested in 0.01% or 19,027 shs. Driehaus Lc holds 0.17% of its capital in Cerus Corporation (NASDAQ:CERS) for 870,678 shs. Primecap Mgmt Ca reported 10.30 million shs stake. Element Capital Management Ltd Llc reported 18,827 shs. Elk Creek Prtnrs Ltd Liability invested in 2.26% or 7.06M shs. Northern has invested 0% in Cerus Corporation (NASDAQ:CERS). Salzhauer Michael has 429,762 shs. Rhumbline Advisers holds 0% of its capital in Cerus Corporation (NASDAQ:CERS) for 107,397 shs. Millrace Asset Gp stated it has 386,202 shs or 2.05% of all its holdings. Budros Ruhlin And Roe Inc holds 0.03% or 18,970 shs. State Common Retirement Fund holds 155,749 shs or 0% of its capital.

Cerus Corporation registered $1.32 million net activity with 1 insider buy and 11 selling transactions since March 10, 2018. On Saturday, March 10 the insider Greenman William Mariner sold $87,795. Green Kevin Dennis sold $468,822 worth of stock or 73,000 shs. The insider Benjamin Richard J sold 3,680 shs worth $18,328. On Friday, May 11 Moore Carol also sold $380,865 worth of Cerus Corporation (NASDAQ:CERS). On Friday, June 8 SCHULZE GAIL had sold 52,500 shs worth $349,125. The insider Menard Chrystal sold 4,610 shs worth $22,793.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

Total analysts of 2 have positions in Cerus Corp (NASDAQ:CERS) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since January 8, 2018 according to StockzIntelligence Inc Cerus Corp has 4 analyst reports. In Monday, January 8 report Cantor Fitzgerald maintained the stock with “Buy” rating. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, March 8. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, May 8. On Wednesday, January 24 Robert W. Baird maintained Cerus Corporation (NASDAQ:CERS) with “Buy” rating. Listed here are Cerus Corporation (NASDAQ:CERS) PTs and latest ratings.

08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $7.0000 Maintain
08/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $6.0 Maintain
24/01/2018 Broker: Robert W. Baird Rating: Buy New Target: $6.0 Maintain
08/01/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $5.0 Maintain

CERS is reaching $6.65 during the last trading session, after decreased 2.21%.Currently Cerus Corporation is uptrending after 221.29% change in last June 29, 2017. CERS has also 176,334 shares volume. CERS outperformed by 208.72% the S&P500.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.The company has $868.12 million market cap. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.Currently it has negative earnings. The companyÂ’s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

More recent Cerus Corporation (NASDAQ:CERS) news were announced by Benzinga.com, Nasdaq.com and Benzinga.com. The first one has “28 Stocks Moving In Wednesday’s Pre-Market Session” as a title and was announced on June 20, 2018. The next is “Report: Developing Opportunities within Torchmark, Cerus, American Equity Investment Life Holding, Southern Copper …” on June 28, 2018. And last was announced on June 21, 2018, called “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street”.

Cerus Corporation (NASDAQ:CERS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.